Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSTEOGROW-B
- Development stage
- Unknown
- Lead developer
- Genera Research
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Implant
01
Overview
**OSTEOGROW-B** is a Genera Research investigational bone-regeneration implant for transforaminal lumbar interbody fusion. It comprises recombinant human bone morphogenetic protein 6 delivered in an autologous blood coagulum and enriched with host bone harvested from the patient's spine. BMP6 provides an osteoinductive signal intended to promote new bone formation and accelerate vertebral fusion. Genera Research reports that OSTEOGROW-B was evaluated in a completed multicentre, double-blinded randomized Phase I/II trial in 60 patients undergoing transforaminal lumbar interbody fusion.
02
Targets
ACVR2A/B (Activin receptor type-2A (ACVR2A) and Activin receptor type-2B (ACVR2B))BMPR1ABMPR1BBMPR2 (Bone morphogenetic protein receptor type II)BMP6 (Bone morphogenetic protein 6)
Beyond the preview
Go deeper on OSTEOGROW-B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSTEOGROW-B.